Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene Therapies

January 2, 2024

https://www.globenewswire.com/news-release/2024/01/02/2802564/36461/en/Voyager-Therapeutics-Enters-Capsid-License-Agreement-and-Strategic-Collaboration-with-Novartis-to-Advance-Novel-Gene-Therapies.html

– Collaboration with gene therapy leader Novartis aims to discover and develop new approaches for Huntington’s disease and spinal muscular atrophy –

– Voyager to receive up-front consideration of $100 million and is eligible to receive milestone payments and tiered royalties –

Read more at globenewswire.com

Related news for (VYGR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.